ARTICLE | Company News
Arakis, KS Biomedix deal
March 12, 2001 8:00 AM UTC
The companies will co-develop Arakis' AD 452 single isomer cytokine modulator and KSB's KSB306/7 anti-edemic cell redox modulator, which are in preclinical development. The companies will jointly fun...